Mayo Clinic Laboratories > BioPharma Diagnostics > Testing > Infectious diseases

INFECTIOUS DISEASES

A WEALTH OF TESTING EXPERIENCE

BioPharma Diagnostics offers access to the infectious disease testing capabilities of Mayo Clinic’s internationally renowned clinical microbiology laboratories. With more than 70 years of testing experience, our laboratories span all areas of conventional and molecular medical microbiology, offering a broad selection of tests designed for rapid identification and in-depth characterization of the bacterial, viral, fungal, and parasitic agents of infectious diseases.

Performing more than four million tests annually, our seven clinical microbiology laboratories have developed and implemented in vitro and culture techniques, immunoassays, antimicrobial susceptibility testing, and molecular methods for rapid detection, identification, and characterization of microbial pathogens.

Our laboratories are managed by physician-scientists, many of whom are actively engaged in clinical practice and research. Through BioPharma Diagnostics, our partners have access to a wealth of world-renowned expertise to help guide test ordering and interpret results.

To learn more about our testing, view our biopharma-specific test catalog and full test catalog.

Test menu

Full suite of infectious disease testing Full suite of infectious disease testing
Full suite of infectious disease testing

Our internationally renowned clinical microbiology laboratories offer a broad selection of tests designed for rapid identification and in-depth characterization of the causative agents of infectious diseases. We have developed and implemented culture techniques, immunoassays, antimicrobial susceptibility testing, and molecular methods for rapid detection, identification, and characterization, as well as provision treatment guidance for microbial pathogens.

Fungal infections Fungal infections
Fungal infections

Our comprehensive fungal infection testing menu is supported by ongoing innovation and development of novel testing methods and strategies and enable detection of a wide range of clinically significant pathogens, including newly emerging species.

Helicobacter pylori Helicobacter pylori
Helicobacter pylori

Find out why timely, accurate diagnosis of H. pylori is critical for improving patients’ gastrointestinal health and preventing further harm.

Infectious disease pathology Infectious disease pathology
Infectious disease pathology

Our practice provides regular exposure, not only to the common infections, but also to uncommon infections that most pathologists may only see once in their careers.

Vector-borne diseases Vector-borne diseases
Vector-borne diseases

Our internationally renowned clinical microbiology laboratories span all areas of conventional, molecular, and serological medical microbiology, offering a broad selection of tests designed for rapid identification and in-depth characterization of the pathogens associated with infectious diseases.

Comprehensive disease testing

Through BioPharma Diagnostics, our partners have access to Mayo Clinic Laboratories’ infectious disease test catalog, including testing for:

  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
  • Helicobacter pylori
  • Infectious disease pathology
  • Vector-borne diseases
  • HIV and hepatitis

Our molecular testing methods include:

  • Polymerase chain reaction (PCR) testing
  • Advanced whole genome microbial sequencing
  • Targeted metagenomic sequencing
  • Matrix-assisted laser-desorption/ionization-time of flight (MALDI-TOF) mass spectrometry organism identification

In addition to using clinically available testing, BioPharma Diagnostics partners can access infectious disease testing for clinical trials and be among the first to use up-and-coming tests currently in development.

News and updates

The latest

Dr. Morice discusses lab market trends with the Advisory Board

William Morice II, M.D., Ph.D., recently joined the Advisory Board for a webinar discussion on 2024 lab market trends. Dr. Morice covered the current lab market outlook, the priority trends, and opportunities for future growth.

Learn more
What’s Causing Outbreaks of Preventable Infectious Diseases: Bill Morice, M.D., Ph.D.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss recent outbreaks in vaccine-preventable diseases.

Preparing for Respiratory Viruses: Bill Morice, M.D., Ph.D.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss practical steps for protecting yourself and innovations that are making testing and vaccination easier.

Dr. Morice discusses lab market trends with the Advisory Board

William Morice II, M.D., Ph.D., recently joined the Advisory Board for a webinar discussion on 2024 lab market trends. Dr. Morice covered the current lab market outlook, the priority trends, and opportunities for future growth.

Metagenomic Sequencing — A Tool for Diagnosis of Central Nervous System Infection

PACE / State of FL This webinar will cover metagenomic sequencing for diagnosing central nervous system infection. Content will be shared regarding technical details, clinical applications, and results interpretation, drawing on both current literature and practice guidelines.

Why Mpox is a Public Health Emergency: Matthew Binnicker, Ph.D.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Matthew Binnicker, Ph.D., professor of laboratory medicine and pathology and clinical virologist at Mayo Clinic. They discuss the upsurge of mpox cases, particularly in Africa, and why the World Health Organization has declared it a public health emergency of international concern.

Tracking the Latest Pathogens: Bill Morice, M.D., Ph.D.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss what’s new and ongoing with pathogens and infections.

Alarming Increase in Dengue Cases: Elitza Theel, Ph.D.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Elitza Theel, Ph.D., director of the Infectious Diseases Serology Laboratory at Mayo Clinic, to discuss the increase of dengue cases in the United States and around the world.

COVID-19 and Avian Flu: Bill Morice, M.D., Ph.D.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the summertime activity of COVID-19 and the latest updates with avian influenza (H5N1).

Infectious Diseases on the Move: Bill Morice, M.D., Ph.D.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss why measles remains a virus of concern, how avian flu continues to spread, and new developments in the federal regulation of laboratory-developed tests.

Widening the net to capture elusive pathogens

Central nervous system infections, such as meningitis and encephalitis, can be devastating for affected patients. While specific treatments are available for some of these infections, it first requires identifying the precise cause of infection. To meet that need, Mayo Clinic Laboratories has developed a metagenomics assay that can identify more than 1,000 pathogenic organisms in cerebrospinal fluid. The innovative assay, which uses an approach known as shotgun metagenomic sequencing, is one of the only such tests currently available.

Avian Flu Outbreaks and New COVID-19 Variants: Matthew Binnicker, Ph.D.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Matthew Binnicker, Ph.D., professor of laboratory medicine and pathology and clinical virologist at Mayo Clinic. They discuss the widespread outbreaks of H5N1 bird flu and the new “FLiRT” variants of COVID-19.

The Growing Crisis of Antimicrobial Resistance: Robin Patel, M.D.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Robin Patel, M.D., director of the Infectious Diseases Research Laboratory and co-director of the Bacteriology Laboratory at Mayo Clinic. They discuss antimicrobial resistance and why it’s a major global health concern.

View More
INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.